Why the study?
Assessment of arterial stiffness is a substantial prognostic factor for cardiovascular complications, and this review analyzes data from studies where CAVI is used to evaluate arterial wall stiffness in magistral vessels.
Does Cardio-ankle vascular index (CAVI) measurement improve risk and severity evaluation of magistral vessels lesion in patients with cardiovascular diseases and type 2 diabetes?
Does Cardio-ankle vascular index (CAVI) measurement improve risk and severity evaluation of magistral vessels lesion in patients with cardiovascular diseases and type 2 diabetes?
CAVI is a valuable, blood pressure-independent non-invasive tool for assessing arterial stiffness and cardiovascular risk in patients with atherosclerosis, hypertension, and type 2 diabetes.
Assesment of arterial stiffness the substantional prognostic factor for evaluating complications of cardiovascular diseases (CVD) in patients with atherosclerosis, hypertension and type 2 diabetes, may be performed using different parameters, including cardio-ankle vascular index (CAVI). The main purpose of this review is to analyze data from studies where CAVI is used to test the arterial wall stiffness in magistral vessels. CAVI measurement is non-invasive and performed by portable devices which makes it comfortable for ambulatory use in patients who come for a check-up and also in those who already are hospitalized. It does not require any special knowledge from investigator and the test lasts a couple of minutes long. CAVI does not depend on blood pressure changes and is more specific in structural changes of arterial wall assessment than brachial-ankle pulse wave velocity (baPWV). CAVI shows considerable correlation with markers of CVD like atherosclerotic plaques in vessels, diastolic disfunction of left ventricle and angina pectoris. CAVI may be used for early monitoring and assessing the lesions of target organs in patients with atherosclerosis, chronic hypertension and type 2 diabetes. Establishing CAVI as a standart parameter in assessing patients who are at risk of CVD can help to improve complications prevention, reduce mortality and prolong their lifespan.
No takes yet. Share an insight, caveat, or question.
Verner et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: